Industrial automation and pharma automation are not the same thing Pharmaceutical manufacturing automation shares surface-level similarities with industrial automation — both involve sensors, PLCs, SCADA systems, and process control software. But pharmaceutical automation operates under regulatory constraints that fundamentally change the engineering approach. Every automated system in a GxP environment must be validated, every change must be controlled, every data point must be attributable and immutable, and every system modification must be assessed for regulatory impact. A company that automates automotive assembly lines cannot simply apply the same approach to pharmaceutical manufacturing. The technology may overlap, but the quality system requirements, documentation obligations, and regulatory oversight create a different engineering environment entirely. This is the practical lens through which our overview of proven AI use cases in pharmaceutical manufacturing frames vendor selection: the underlying ML or control technology is rarely the bottleneck — the validation envelope around it is. What distinguishes pharma automation specialists Capability Generic automation vendor Pharma automation specialist GxP validation May offer as add-on service Core competency, integrated into delivery Change control Standard change management FDA/EMA-aligned change control with impact assessment Data integrity Standard audit logging ALCOA+ compliance, 21 CFR Part 11/Annex 11 adherence Regulatory awareness Limited Current knowledge of FDA guidance, EU GMP Annexes, ICH guidelines Documentation Standard project documentation Validation-ready deliverables (URS, FS, DS, IQ/OQ/PQ protocols) Post-deployment support Break-fix maintenance Validated-state maintenance, periodic review support The right-hand column is not a marketing checklist. Each line corresponds to an obligation that, if missed, surfaces during a regulatory inspection rather than during user acceptance testing — which is the most expensive moment to discover it. Evaluation criteria for pharma automation partners When selecting an automation partner for pharmaceutical manufacturing, assess these capabilities: Demonstrated GxP track record. Have they delivered validated systems in pharmaceutical manufacturing environments? Can they provide reference sites (anonymised if necessary) where their systems passed regulatory inspection? Validation methodology. Do they follow GAMP 5 principles? Can they articulate a risk-based validation approach for the specific system type? Do they deliver validation-ready documentation as part of their standard deliverables? Regulatory currency. Are they current with recent regulatory changes? GAMP 5 Second Edition (2022), EU GMP Annex 1 (2023), FDA CSA guidance (2022), and ICH Q12 — a qualified partner should be able to discuss how these affect the proposed system, not list them as résumé items. Data integrity architecture. How do they implement audit trails, electronic signatures, and access controls? Can they demonstrate ALCOA+ compliance in their delivered systems, including for the ML or computer-vision components, not just the surrounding MES layer? AI/ML capability. If the automation includes machine learning components (computer vision, predictive maintenance, process control), does the partner have validated AI deployment experience? In our experience, integrating ML into a validated pharma environment is where most automation vendors discover that their familiar PyTorch, TensorRT, or ONNX workflows need to be wrapped in change-controlled deployment pipelines with frozen model artefacts and signed audit trails. Ongoing support model. Post-deployment support for validated systems is not standard IT support. It requires change control compliance, re-validation capabilities, and regulatory awareness for system modifications. A break-fix SLA is not a substitute for a validated-state maintenance contract. The build-vs-buy decision Pharmaceutical companies face a recurring decision: build automation capability internally or partner with specialist vendors. Internal development offers control and intellectual property ownership but requires sustained investment in both automation engineering and GxP validation expertise. External partnerships offer speed and specialist knowledge but introduce supplier management obligations and dependency risks. The pragmatic approach is a hybrid. Develop internal competency in automation strategy, system architecture, and validation oversight; partner with specialists for system implementation, integration, and domain-specific expertise. This preserves strategic control while accessing specialist capability where it has the greatest impact. The broader context — how this decision sits inside an end-to-end manufacturing intelligence roadmap — is something we cover in our discussion of Pharma 4.0 and manufacturing intelligence. How do you evaluate a technology partner’s pharma domain expertise? The most reliable indicator of pharma domain expertise is not marketing material but evidence of previous validated deployments. Request specific examples: which regulatory frameworks (GMP, GxP, 21 CFR Part 11, EU GMP Annex 11) the partner has implemented against, which validation protocols they followed, and whether they can provide references from regulated environments. A technology partner without pharma experience will underestimate validation effort substantially and deliver systems that function correctly but lack the documentation, audit trails, and change control procedures that regulators require. We have seen projects where a technically excellent system was rejected during a regulatory inspection because the vendor did not implement electronic signature controls to 21 CFR Part 11 requirements — a feature that adds modest development effort if planned from the start but requires significant rearchitecture if added after deployment. This is an observed pattern across our pharma engagements, not a benchmarked failure rate. Our vendor evaluation checklist includes: demonstrated understanding of validation lifecycle phases (IQ, OQ, PQ), experience with validation documentation (URS, FS, DS, test protocols, traceability matrices), familiarity with risk-based approaches (GAMP 5 risk assessment methodology), and a team with direct regulatory inspection experience. A vendor who can explain how their system would be presented during an FDA inspection has the practical knowledge that distinguishes informed implementation from superficial compliance. The cost of selecting a non-pharma-experienced technology partner becomes apparent during the validation phase, not the development phase. Development may proceed on schedule, but validation — which requires tracing every requirement to a design specification, every design specification to a test protocol, and every test protocol to executed evidence — reveals gaps in documentation practices that delay deployment by months. The specifics of how this plays out for AI in pharmaceutical drug manufacturing and production make the cost concrete: a model that performs well in offline evaluation but lacks reproducible inference artefacts cannot be validated, regardless of its accuracy. FAQ The pattern across all six questions is the same: the AI is not the hard part. The validated envelope around the AI is.
